 |
| |
| In my opinion, two key aspects differentiate Hemostemix within the cell therapy marketplace and position its technology to be disruptive. Firstly, it has world-class proficiency in peripheral blood stem cells, and these cells are sourced through a simple blood draw from the arm. Secondly, it controls a proprietary technology platform that can be applied across a wide range of disease indications. This combination positions Hemostemix for both therapeutic and commercial success. Read more... |
|
|
|
|
| |
| NEW YORK, Nov. 19, 2018 — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases, announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of NurOwn® in patients with progressive multiple sclerosis (MS). |
|
|
|
|
| |
| InVitria, a division of Ventria Bioscience, was created to provide the biotechnology industry with innovative products to improve cell culture and biomanufacturing. InVitria accomplishes this by allowing customers to eliminate animal components from cell-based processes. Removing these components helps to improve consistency, safety and efficiency. In this interview with Dr. Alfano, we explore the formation of InVitria, as well as its innovative product portfolio, mission, and future goals. |
|
|
|
|
| |
| TBL Performance Plastics (TBL) has over 50 years of experience in plastics and related life science industries. I became interested in the company, because it offers fully-integrated manufacturing capabilities that could support the explosive growth of the cell and gene therapy (CGT) industry, where there is an ever-expanding need for manufacturing equipment to support the production of innovative products. One of TBL’s most compelling products is its aSURE™ instrument fitting, which was designed to be a better alternative to single-use pressure sensors. |
|
|
|
|
| |
| Rockville, MD (November 1, 2018) – Propagenix Inc., a privately-held biotechnology company focused on developing proprietary cellular technologies for regenerative medicine, has published a peer-reviewed article and been granted several US patents on its core technology for bioproduction of human epithelial stem cells, known as EpiX™ technology. |
|
|
|
|
| |
| After hosting a successful 2018 event, the AAOSCP has announced the dates for its 2019 Scientific Congress to be held May 3-5, 2019 in Miami. The AAOSCP is an organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. |
|
|
|
|
| |
| ALACHUA, Fla., Oct. 29, 2018 — AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, reported that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to Avance® Nerve Graft. |
|
|
|
|
| |
| The past 12 months have have seen major advances in the clinical applications of iPSCs, with Cynata Therapeutics progressing the world's first formal trial of an iPSC-derived cell therapeutic. With multiple physician-led iPSC studies also underway in Japan for applications ranging from Parkinson's disease to heart disease, the iPSC market is poised to for burgeoning growth. There has also been dramatic progress with production and differentiation technologies related to iPSCs, as well as growing use of iPSCs within drug discovery, disease modelling, tissue engineering, and precision medicine. |
|
|
|
|
| |
| Boston BioLife is excited to announce its upcoming Regenerative Medicine Workshop in Orlando, Florida, at the amazing Omni Resort at Championsgate from November 29 - December 2nd, 2018. Boston BioLife is an organization that provides cutting-edge workshops and educational programs to physicians and scientists interested in learning about regenerative medicine. Will I see you there? |
|
|
|
|
| |
| HemaCare Corporation (OTCMKTS: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, announces their involvement as a provider of leukapheresis process development material for 100% of the current FDA-approved immunocellular therapies, Kymriah® (Novartis; Switzerland), Yescarta® (Kite, a Gilead Company; CA, USA), and Provenge® (Dendreon; WA, USA). |
|
|
|
|
| |
| SAN DIEGO, Nov. 05, 2018 — Poseida Therapeutics announced the U.S. FDA granted a RMAT designation to P-BCMA-101, Poseida’s lead CAR-T therapeutic candidate currently in a Phase 1 clinical trial for the treatment of patients with relapsed/refractory multiple myeloma. RMAT designation includes all of the benefits of the Fast Track and Breakthrough Therapy designation programs, including early interactions with the FDA. |
|
|
|
|
| |
| To characterize the rapidly growing Regenerative Medicine (RM) Industry, this database features 650+ companies worldwide that are developing RM products for therapeutic use in humans. It was originally developed in-house for our own purposes, but we have had more and more readers requesting access to it. To celebrate the Thanksgiving holiday, you can claim this searchable, sortable database of 650+ regenerative medicine companies for only $97 (50% off). |
|
|
|
|
| |
| In recent months, exosome start-ups have been the recipients of approximately $386.2 million in investor funding. Clearly, investors are feeling favorable toward companies developing exosome technologies and there is a growing evidence that the industry is poised for growth. To date, four companies have dominated the funding landscape: Codiak Biosciences, Exosome Diagnostics, Evox Therapeutics, and ExCoBio. For the next 48 hours, you can claim this 134-page report for 50% off and get instant access to exosome market insights, including market size, segmentation, and 5-year forecasts. Act now, before this offer expires! |
| |
|
|
|
|
